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Efficacy of Low-Dose Amitriptyline for Chronic Low Back Pain
A Randomized Clinical Trial
Donna M. Urquhart, PhD; Anita E. Wluka, PhD; Maurits van Tulder, PhD; Stephane Heritier, PhD;
Andrew Forbes, PhD; Chris Fong, MBBS; Yuanyuan Wang, PhD; Malcolm R. Sim, PhD;
Stephen J. Gibson, PhD; Carolyn Arnold, MBBS; Flavia M. Cicuttini, PhD
IMPORTANCE Antidepressants at low dose are commonly prescribed for the management of
chronic low back pain and their use is recommended in international clinical guidelines.
However, there is no evidence for their efficacy.
OBJECTIVE To examine the efficacy of a low-dose antidepressant compared with an active
comparator in reducing pain, disability, and work absence and hindrance in individuals with
chronic low back pain.
DESIGN, SETTING, AND PARTICIPANTS A double-blind, randomized clinical trial with a 6-month
follow-up of adults with chronic, nonspecific, low back pain who were recruited through
hospital/medical clinics and advertising was carried out.
INTERVENTION Low-dose amitriptyline (25 mg/d) or an active comparator (benztropine
mesylate, 1 mg/d) for 6 months.
MAIN OUTCOMES AND MEASURES The primary outcome was pain intensity measured at 3 and
6 months using the visual analog scale and Descriptor Differential Scale. Secondary outcomes
included disability assessed using the Roland Morris Disability Questionnaire and work
absence and hindrance assessed using the Short Form Health and Labour Questionnaire.
RESULTS Of the 146 randomized participants (90 [61.6%] male; mean [SD] age, 54.8 [13.7]
years), 118 (81%) completed 6-month follow-up. Treatment with low-dose amitriptyline did
not result in greater pain reduction than the comparator at 6 (adjusted difference, −7.81;
95% CI, −15.7 to 0.10) or 3 months (adjusted difference, −1.05; 95% CI, −7.87 to 5.78),
independent of baseline pain. There was no statistically significant difference in disability
between the groups at 6 months (adjusted difference, −0.98; 95% CI, −2.42 to 0.46);
however, there was a statistically significant improvement in disability for the low-dose
amitriptyline group at 3 months (adjusted difference, −1.62; 95% CI, −2.88 to −0.36).
There were no differences between the groups in work outcomes at 6 months (adjusted
difference, absence: 1.51; 95% CI, 0.43-5.38; hindrance: 0.53; 95% CI, 0.19-1.51), or 3 months
(adjusted difference, absence: 0.86; 95% CI, 0.32-2.31; hindrance: 0.78; 95% CI, 0.29-2.08),
or in the number of participants who withdrew owing to adverse events (9 [12%]
in each group; χ2 = 0.004; P = .95).
CONCLUSIONS AND RELEVANCE This trial suggests that amitriptyline may be an effective
treatment for chronic low back pain. There were no significant improvements in outcomes at
6 months, but there was a reduction in disability at 3 months, an improvement in pain
intensity that was nonsignificant at 6 months, and minimal adverse events reported with a
low-dose, modest sample size and active comparator. Although large-scale clinical trials that
include dose escalation are needed, it may be worth considering low-dose amitriptyline if the
only alternative is an opioid.
TRIAL REGISTRATION anzctr.org.au Identifier: ACTRN12612000131853
JAMA Intern Med. 2018;178(11):1474-1481. doi:10.1001/jamainternmed.2018.4222
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L ow back pain (LBP) is the largest contributor to disabilityworldwide.1 Althoughtherearearangeoftreatmentsavail-able for LBP, the efficacy of these therapies are limited.2
Antidepressants are a commonly prescribed treatment for LBP
in clinical practice.3 Typically, higher doses of antidepressants
are used to treat depression, whereas low doses are prescribed
for chronic pain, with the analgesic effects of the drug occurring
independent of depression.4 The use of antidepressants is rap-
idly increasing, with an increase in prescriptions of 3.9 million
(6.8%) over 12 months in the United Kingdom5 and 29% of these
reported to be off label (unapproved indication).6 This is despite
the lack of evidence from systematic reviews7 and conflicting
recommendations in clinical guidelines.8
A review of national and international guidelines has high-
lighted that not only do recommendations for antidepressant
treatment for LBP vary substantially, but 7 of 14 guidelines
recommend their use, with none indicating whether they should
be prescribed in high or low doses.8 Two treatment guidelines
published in 2016 to 2017 provide further conflicting recommen-
dations, 1 stating that while tricyclic antidepressants (TCAs) and
selective serotonin reuptake inhibitors are not recommended,
duloxetine hydrochloride should be considered as a second-line
therapy,9 whereas the other did not recommend the use of any
class of antidepressant for chronic LBP.10
A number of systematic reviews, including our Cochrane
systematic review,7 have concluded that there is no clear evi-
dence that antidepressants are more effective than placebo for
LBP.11-13 They have highlighted the need for high-quality trials
and identified limitations of previous studies including insuf-
ficient blinding, small sample sizes, and short treatment and
follow-up periods (≤3 months). Moreover, no studies have ex-
amined the effectiveness of a low-dose TCA, a common method
of prescribing for LBP. Amitriptyline hydrochloride is a TCA
widely used in low doses to treat pain,6,14 particularly nonspe-
cific LBP,3 independent of depression.4 However, there is no
evidence to support its widespread use.
Thus, the aim of this double-blind, randomized clinical trial
was to determine whether low-dose amitriptyline is effective
in reducing pain, disability, and work absence and hindrance
over 6 months in those with chronic, nonspecific LBP com-
pared with an active comparator.
Methods
This study is a double-blind, randomized clinical trial, with a
2-arm, parallel-group, superiority design. The trial was registered
at the Australian New Zealand Clinical Trials Registry
(ACTRN12612000131853) prior to recruitment. Ethics approval
was obtained from the Alfred Hospital Ethics Committee (HREC
/12/Alfred/16:476/11), Monash University Human Research Ethics
Committee(CF12/0271-2012000106),andEasternHealthHuman
Ethics Committee (SERP28/1112). Trial reporting was guided by
the CONSORT guidelines.15 The study protocol has been
published16 and is available in Supplement 1.
Sample
A total of 146 individuals with chronic LBP were recruited
through hospital, medical, and allied health clinics and
advertising in local media. Written informed consent was
obtained prior to study commencement.
We recruited men and women aged 18 to 75 years with
chronic, nonspecific LBP, defined as pain below the costal mar-
gin and above the gluteal folds, without a specific cause and
which had been present for greater than 3 months.17 Participants
with any of the following were excluded: pathological entity,
major coexisting illness that might confound function or for
which amitriptyline may be contraindicated, another significant
musculoskeletal condition, history of psychosis, current or
previously diagnosed depression with or without the use of
medication, prior or current use of antidepressants, current use
of opioids, any contraindication or allergy to amitriptyline, preg-
nancy, planning or trying to become pregnant or breastfeeding,
or inability to give informed consent.
Randomization and Blinding
Randomizationwasbasedoncomputer-generatedrandomnum-
bers prepared by a statistician who had no involvement in trial
conduct. Participants were allocated in a ratio of 1:1 to either the
interventionoractivecomparatorgroup.Althoughitwasplanned
that block randomization based on hospital site would be used
to stratify, most participants were recruited through advertising
so this was not required. The use of a central allocation that in-
volved pharmacy-controlled randomization ensured that the
allocation could not be accessed by research personnel. Alloca-
tion concealment and double blinding was ensured by the follow-
ing means: dispensing of medications by the hospital clinical trial
pharmacy, use of an identical comparator tablet that mimicked
the adverse events of amitriptyline, and questionnaire data that
was collected by research assistants blinded to group allocation.
Study Intervention
Participants in the intervention arm received a low-dose TCA,
25 mg of amitriptyline (Alphapharm Pty Ltd), and those in the
control arm received an active comparator, 1 mg benztropine
mesylate (Phebra Pty Ltd). These were administered in identical
capsules to be taken in a single dose at the same time each day for
6months.Weselectedbenztropine,anactivecomparatorbecause
it mimics adverse events of amitriptyline while having no known
effect on chronic pain.18,19 Cost of medication was funded by the
Key Points
Question Is a low-dose tricyclic antidepressant effective in the
treatment of chronic low back pain?
Findings In this randomized clinical trial of 146 participants with
chronic low back pain, the use of low-dose amitriptyline did not
demonstrate an improvement in pain, disability, or work at 6
months compared with an active comparator. However, there was
a reduction in disability at 3 months, an improvement in pain
intensity that was nonsignificant at 6 months, and minimal
adverse events reported for the treatment group.
Meaning These results suggest that low-dose amitriptyline may
be an effective treatment for chronic low back pain; although
large-scale trials are needed, it may be worth considering
amitriptyline, especially if the alternative is opioids.
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study, with no sponsorship from industry. All participants
were provided with usual care by their treating practitioners,
and the use of nonopioid analgesics and nonsteroidal anti-
inflammatory agents was allowed.
Study Procedure
Potential participants were telephone screened using a question-
naire to determine their eligibility. They then attended the study
centerforanassessmenttoconfirmeligibilityandobtaininformed
consent.Eligibleparticipantswererandomized,completedabase-
line assessment, and received the first 3 months of amitriptyline
or comparator from the Alfred Hospital Clinical Trials Pharmacy.
Participants were contacted by telephone at 2 weeks, 1 to 2
months, 3 months, 4 to 5 months, and 6 months to monitor their
progress and any adverse events. The 3- and 6-month outcome
questionnaires and the second 3 months of medication were sent
to the participants by mail. The same researchers, blinded to
treatment allocation, administered questionnaires, monitored
adherence, and recorded adverse events. Participants’ adherence
to trial medication was defined as the return of empty medica-
tion bottles at 6 months. Participants were not paid for their par-
ticipation but were reimbursed for parking and transport costs.
Outcome Measures
Outcome measures were administered by research assistants
blinded to group allocation at baseline and 3 and 6 months. The
primaryoutcomemeasurewascurrentlevelofpainintensitymea-
sured at 6 months using a 100-mm visual analog scale (VAS). The
Descriptor Differential Scale (DDS; range, 0-20), a valid measure
of pain intensity,20 was also assessed because it has been used in
a previous LBP trial of antidepressants.21
The secondary outcome of disability was assessed using
the Roland Morris Disability Questionnaire (RMDQ),22 a vali-
dated instrument designed to assess self-rated low back dis-
ability. Greater levels of disability are reflected by higher num-
bers, and scores are sensitive to change over time.23 We
examined absenteeism and hindrance in performance of paid
and unpaid work using the Short Form Health and Labour
Questionnaire, a validated questionnaire for examining work
outcomes in relation to injury.24
Additional Outcomes
Global improvement was measured using a 6-point Likert
scale (range, “much worse” to “completely recovered”).25
General health status, depression, and fear of movement
and/or (re)injury were measured using the EuroQol Instrument
(version, EQ-5D-5L),26 Beck Depression Inventory,27 and Tampa
scale,28 respectively.
Other Measures
Height, weight, and body mass index (calculated as weight in
kilograms divided by height in meters squared) were measured
atbaseline.Werecordedanyassociatedcompensationclaimsand
the nature of these claims. The presence of neuropathic pain was
assessed using the painDetect questionnaire, with scores of 19
or greater reflecting a neuropathic component.29
AdverseeventswereassessedusingtheUKUSide-EffectsRat-
ing Scale,30 a validated questionnaire for assessing the severity
and impact of adverse events on daily function due to psychotro-
pic medication. Adverse events were examined at baseline, 2
weeks, and 2, 4, and 6 months. Adverse events were assessed
according to their psychotropic, neurological, autonomic, or
“other” nature and were recorded as mild, moderate, or severe.
Details of major adverse events were reported to the ethics
committees.
Sample Size Calculation
We determined that 150 patients (75 per group) would be
needed to provide the trial with 90% power to detect a mini-
mal clinically important difference (MCID) in pain intensity (15
points on 100-mm VAS25,31) and disability (3 points on
24-point RMDQ32) between the groups at 6 months. This was
assuming a 2-sided α level of .05 and mean (SD) for pain and
disability of 2.5 (5) points and a maximum 20% withdrawal rate.
Statistical Analysis
Analyses were based on intention to treat. Summary statistics
comparingrandomizedarmsatbaselineweretabulated.Continu-
ous outcomes were analyzed using analysis of covariance, and
logistic regression was performed for binary outcomes, with ad-
justments for baseline measurements where appropriate. Mul-
tipleimputationbychainedequations33 wasusedtoimputemiss-
ing 3- and 6-month pain, disability, and work data by treatment
arm. A responder analysis was conducted in accordance with the
National Institutes of Health Task Force Research Standards,34
using the MCIDs for pain25,31 and disability32 (as described herein)
to define a responder, and logistic regression for the analysis. The
percentagesofindividualswithmoderateorsevereadverseevents
were calculated based on treatment, and differences between
groups at baseline and 6 months, and over the 6-month period,
were tested using χ2 tests and generalized estimating equations
for repeated measures, respectively. SPSS Statistics, version 22.0
(IBM Corp), was used and P < .05 was considered significant.
Results
From April 30, 2012, until June 1, 2016, 876 participants were
screened and 146 randomized, with 72 allocated to the low-dose
amitriptyline group and 74 to the active comparator group
(Figure 1). The mean (SD) age of participants was 54.8 (13.7) years,
mean (SD) body mass index was 29.4 (5.8), and 90 (62%) were
men. Participants had a mean (SD) pain score of 41.6 (20.8) and
disability score of 7.9 (4.5). A total of 35 (25%) and 117 (85%)
participants reported work absence and hindrance owing to
LBP, respectively. Baseline characteristics of participants are
presented in Table 1.
Outcomes at 6 months were completed by 118 (81%) partici-
pants.Althoughthenumberofparticipantswhodidnotcomplete
the 6-month outcomes was small, we found no significant differ-
ences between participants who completed them and those who
did not (eTable 1 in Supplement 2). A total of 53 (71%) participants
in the active comparator group and 50 (70%) in the treatment
group were found to be adherent to the study treatment.
Table 2 presents the results for the primary and secondary
outcomes. Although the low-dose amitriptyline group
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reported an adjusted mean (SE) reduction in pain intensity of
12.6 (2.7) points on the VAS from baseline to 6 months com-
pared with a 4.8 (2.9)-point reduction for the active compara-
tor group, treatment with low-dose amitriptyline did not re-
sult in a greater pain reduction at 6 months (adjusted difference,
−7.81; 95% CI, −15.7 to 0.10) or 3 months (adjusted difference,
−1.05; 95% CI, −7.87 to 5.78) (Figure 2). When multiple impu-
tation was performed, the effect of low-dose amitriptyline on
pain at 6 months was not significant (adjusted difference, −6.70;
95% CI, −14.4 to 1.04). There was no statistically significant
difference in disability between groups at 6 months (adjusted
difference, −0.98; 95% CI, −2.42 to 0.46); however, there was
a statistically significant improvement in disability for the
low-dose amitriptyline group at 3 months (adjusted differ-
ence, −1.62; 95% CI, −2.88 to −0.36) (Figure 2). There were no
significant differences between groups in work absence (odds
ratio [OR], 1.51; 95% CI, 0.43-5.38) or hindrance (OR, 0.53; 95%
CI, 0.19-1.51) at 6 months. Moreover, responder analyses did not
show clinically meaningful differences in pain or disability
between the treatment groups (eTable 2 in Supplement 2).
Table 3 presents data for additional outcomes. At 6 months,
there were no significant differences in global improvement
(adjusted difference, 0.08; 95% CI, −0.77 to 0.92), depres-
sion (adjusted difference, −0.93; 95% CI, −3.34 to 1.49), gen-
eral health (adjusted difference, 5.01; 95% CI, −0.44 to 10.5),
or fear of movement/reinjury (adjusted difference, −2.32; 95%
CI, −4.91 to 0.26) in the treatment group compared with the
active comparator group.
Nine (12%) participants from each group withdrew from the
trial owing to adverse effects (χ2 = 0.004; P = .95). There were no
significant differences between the groups in the percentage of
participants reporting moderate to severe symptoms at baseline
(35%intervention,41%comparator:χ2 = 0.63;P = .43)or6months
(26% intervention, 32% comparator; χ2 = 0.32; P = .58) (eTable
3 in Supplement 2). Although the number of individuals who
experienced moderate to severe symptoms appeared to be lower
at 6 months than at baseline, this was not statistically significant
fortheintervention(35%baseline,26%6months;P = .37)orcom-
parator groups (41% baseline, 32% 6 months; P = .32). While a
similar number of participants in both groups reported an
increase in sleep duration at baseline (8% intervention, 12% com-
parator, χ2 = 3.14; P = .37), more participants in the treatment
group reported an increase in duration of sleep than those in the
comparator group at 6 months (55% intervention, 16% compara-
tor, χ2 = 15.4; P < .001).
Discussion
Toourknowledge,this isthefirstdouble-blind,randomized,con-
trolled trial to examine the efficacy of a low-dose TCA for the
Figure 1. CONSORT Flow Diagram Showing the Flow of Participants
Through the Trial
876 Patients assessed for eligibility
730 Excluded
370 Declined to participate




72 Randomized to receive low-dose
amitriptyline
72 Received low-dose amitriptyline
as randomized
72 Included in the study analyses




58 Completed 3-month outcomes
61 Completed 6-month outcomes
74 Randomized to receive active
comparator
74 Received active comparator
as randomized
74 Included in the study analyses




58 Completed 3-month outcomes
57 Completed 6-month outcomes









Age, mean (SD), y 53.5 (14.2) 56.0 (13.2)
Female sex, No. (%) 28 (39) 28 (38)
Weight, mean (SD), kg 85.9 (20.0) 86.3 (17.4)
Height, mean (SD), m 1.71 (0.09) 1.71 (0.09)
Body mass index, mean (SD) 29.6 (6.03) 29.3 (5.91)
Duration of low back pain, mean (SD), y 13.3 (12.6) 15.2 (13.2)
Neuropathic pain, No. (%)b 9 (13) 8 (11)
Compensation, No. (%) 4 (6) 2 (3)
Depression score, mean (SD)c 10.5 (6.71) 11.2 (8.63)
Paid employment, No. (%) 41 (58) 36 (51)
Pain intensity, mean (SD)d 39.8 (20.5) 43.4 (21.0)
Disability, mean (SD)e 7.54 (4.37) 8.15 (4.54)
Absence from paid/unpaid work, No. (%)f 16 (22) 19 (27)
Hindrance in paid/unpaid work, No. (%)g 56 (81) 61 (88)
Abbreviations: BMI, body mass index (calculated as weight in kilograms divided
by height in meters squared); MCID, minimal clinically important difference.
a For each of the included variables, results were based on available data.
b The presence of neuropathic pain was assessed using the painDetect
questionnaire (ranging from 0 to 38), with scores of 19 or greater reflecting a
high likelihood of a neuropathic component.
c Depression was measured using the Beck Depression Inventory, with scores
ranging from 0 to 63 and higher scores (29-63) indicating more severe
depressive symptoms.
d Pain intensity was assessed using the 100-mm visual analog scale where
participants were asked to rate their current pain, with 0 indicating no pain
and 10 indicating the worst pain imaginable. The MCID was 15 points.
e Disability was measured using the Roland Morris Disability Questionnaire, with
scores range from 0 to 23 and higher scores indicating greater disability. The
MCID was 3 points.
f Assessed using the Short Form Health and Labour Questionnaire. Participants
answered yes or no to whether they were off work during the past month due
to their health.
g Assessed using the Short Form Health and Labour Questionnaire. Participants
answered yes or no to whether their job performance was adversely affected
during the past month due to their health.
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treatment of chronic, nonspecific LBP. Although there were no
significant differences in pain, disability, and work outcomes be-
tween the groups at 6 months, there was an improvement in dis-
ability at 3 months and minimal adverse events reported at 6
months for those treated with low-dose amitriptyline compared
with the active comparator group. Although the improvements
in pain intensity, general health and fear of movement/reinjury
at 6 months did not reach statistical significance, they suggest
that low-dose amitriptytline may have an effect with a larger
sample size. These findings provide support for large-scale clini-
cal trials, with an escalating dose as required, to determine the
treatment effectiveness of amitriptyline.
Previous systematic reviews, which have concluded that
there is no clear evidence that antidepressants are effective for
LBP, have identified major limitations of previous studies and the
needforhigh-qualitytrials.7,11-13 Thepresenttrialaimedtoaddress
these limitations, namely, the lack of investigation of low-dose
antidepressants for pain, insufficient blinding and statistical
power,andshorttreatmentandfollow-upperiods.Weconducted
a double-blind, randomized controlled trial of a low-dose TCA
and compared it with an active comparator, which mimicked the
adverse effects of amitriptyline and optimized blinding. The
presentstudywassufficientlypoweredtodetectaclinicallymean-
ingful effect of low-dose amitriptyline on pain and disability, and
our treatment and follow-up periods were extended beyond
those of previous studies to 6 months. While we did not meet our
primary end point of a reduction in pain at 6 months, treatment
with low-dose amitriptyline resulted in statistically significant
improvements in disability with minimal adverse events, provid-
ing evidence to suggest that amitriptyline may have a thera-
peutic effect for LBP.
This finding is important given that LBP is the leading cause
of disability globally,1 effective treatments for LBP are limited,2
and there is currently an epidemic of escalated usage of nar-
cotics, with more than 50% of narcotic prescriptions issued to
people with LBP.35 Moreover, recent systematic reviews have
reported drug alternatives, such as paracetamol,36 opioid
analgesics,37 and gabapentinoids,38 to be ineffective, leaving
physicians looking for an effective alternative. Amitriptyline
is commonly used for LBP, and its off-label prescription is rap-
idly increasing.6,14 Although TCAs are not recommended in
2016 to 2017 international guidelines,9,10 the use of low-dose
amitriptyline is an attractive option for physicians given its ef-
ficacy in other pain conditions,39,40 and to many patients, who
prefer the use of medications that they believe are simple, cost-
effective, and prevent their condition from becoming worse.41
Moreover, the cornerstone of LBP management is encourag-
ing individuals to stay active and progressively increase their
activity levels.9,10 Given that a variety of factors, including pain,
disability, and fear, are key barriers to activity and that in this
trial we found that low-dose amitriptyline treatment may
address a number of these factors, it is possible that low-dose
Table 2. Treatment Effect on Pain Intensity, Disability, and Work Absence and Hindrance in Individuals With Chronic, Nonspecific Low Back Pain
Parametera













3 mo 6 mo
Difference
(95% CI)b P Value
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(95% CI)b P Value
















































































































































Abbreviation: NA, not applicable.
a Means and standard errors reported at baseline, 3 months, and 6 months.
b Analysis of covariance, adjusted for the baseline score.
c Pain intensity was assessed using the 100-mm visual analog scale where
participants were asked to rate their current pain, with 0 indicating no pain
and 10 indicating the worst pain imaginable. The minimal clinically important
difference was 15 points. Means and standard errors reported at baseline,
3, and 6 months.
d Disability was measured using the Roland Morris Disability Questionnaire, with
scores ranging from 0 to 23 and higher scores indicating greater disability. The
minimal clinically important difference (MCID) was 3 points.
e Assessed using the Short Form Health and Labour Questionnaire (SFHLQ).
Participants answered yes or no to whether they were off work during the past
month due to their health. These are presented as odds ratios (95% CIs)
calculated using logistic regression, adjusted for the baseline score.
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amitriptyline may serve as a valuable treatment for LBP. While
large trials, which include dose escalation, are needed to clarify
the effect of amitriptyline treatment, it may be worth consid-
ering in the management of chronic LBP, especially if the al-
ternative is prescribing opioids.
We found that amitriptyline, prescribed in a low dose,
was well tolerated. There was a similar number of withdraw-
als due to adverse events for both groups, indicating that the
adverse events associated with low-dose amitriptyline are
no greater than those of an active comparator. Of note, we
found that prior to study commencement more than 30% of
participants in each group had moderate to severe symp-
toms that were similar to the adverse events associated with
psychotropic medications.30 Given that these could not be
attributed to the study medications, it suggests that a large
proportion of the symptoms reported by individuals with
chronic LBP who are taking TCAs may not be related to their
medication use. Because low-dose TCAs are commonly pre-
scribed for other conditions, such as headache,40 it is impor-
tant for physicians to be aware of this potential issue. Fur-
thermore, the high proportion of psychotropic symptoms
reported highlights the poor health status associated with
LBP and the need to consider these symptoms in the man-
agement of the condition.
Table 3. Treatment Effect on Global Improvement, General Health, and Psychological Outcomes in Individuals With Chronic, Nonspecific Low Back Paina
Parameter
Mean (SE) Treatment Comparison























3.53 (0.2) 3.80 (0.3) 3.46 (0.3) 3.71 (0.3) 0.08 (−0.77 to 0.92) .86
General
health statusd
69.3 (1.8) 72.9 (2.1) 73.9 (1.8) 71.3 (1.7) 71.3 (2.1) 70.1 (2.2) 3.20 (−1.07 to 7.47) .14 5.01 (−0.44 to 10.5) .07
Depression scoree 10.5 (0.8) 7.59 (0.6) 7.78 (0.8) 11.2 (1.0) 9.06 (0.8) 8.71 (1.0) −0.84 (−2.42 to 0.74) .29 −0.93 (−3.34 to 1.49) .45
Fear of movement/
reinjuryf
37.7 (0.9) 38.0 (0.9) 36.5 (1.0) 38.0 (0.9) 39.0 (0.8) 39.2 (1.2) −0.56 (−2.68 to 1.56) .60 −2.32 (−4.91 to 0.26) .08
a Means and standard errors reported at baseline, 3 months, and 6 months.
b Analysis of covariance, adjusted for the baseline score, with the exception of
“global improvement,” where no adjustment was made because improvement
cannot be assessed at baseline.
c Global improvement was measured using a 6-point Likert scale, ranging from
“much worse” to “completely recovered,” with higher scores indicating greater
improvement.
d General health status was assessed using the EuroQol-Visual Analog Scale
component of the EuroQol Instrument, ranging from 0 being the worst health
you can imagine and 100 being the best health.
e Depression was measured using the Beck Depression Inventory, with scores
ranging from 0 to 63 and higher scores (29-63) indicating more severe
depressive symptoms.
f Fear of movement/(re)injury were measured using Tampa scale. The total
score ranged between 17 and 68, with a high value indicating a greater fear of
movement.
Figure 2. Change in Mean Low Back Pain Intensity and Disability Scores for the Low-Dose Amitriptyline and Active Comparator Groups






























































A, Low back pain intensity was measured using the 100-mm visual analog scale
(greater pain intensity is indicated by higher numbers). B, Low back disability
was assessed using the Roland Morris Disability Questionnaire (0-23 points;
greater levels of disability are reflected by higher numbers). The number of
randomized participants in each of the groups who contributed the data at each
time point is shown at the bottom of the graphs. The P values, derived from the
analysis of covariance, adjusted for baseline score, for the pain intensity and
disability outcomes are also shown. Measurements were performed at baseline
and 3 and 6 months. Error bars indicate standard error of the mean.
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Limitations
This trial has several limitations. We recruited individuals with
chronic, nonspecific LBP, the most common type of LBP. While
thisisapotentiallyheterogeneousgroup,this isawell-recognized
and clinically important population,2 which has been shown to
betheleadingcontributortodiseaseburdenworldwide.1 Weused
well-accepted, standard definitions for LBP and chronicity,2
excluded individuals with a known, pathoanatomical cause for
their LBP, and did not include a subgroup of individuals with a
diagnosis of depression who may have differed in their pain re-
sponse to amitriptyline treatment. We used the VAS and DDS
to assess pain and allow comparison with previous studies.
Although our participants experienced difficulty completing the
DDS, the VAS was completed without issue and provided suffi-
cient data for analysis. We powered this trial to detect statisti-
cal and clinical significant differences in pain and disability based
on previous LBP trials of antidepressants and evidence on
MCIDs for these measures. However, we did not power the trial
to detect differences in our work or additional outcomes and it
is therefore possible that the trial was underpowered in relation
to these. Our follow-up rate was 81%, which is considered accept-
able for a study of short to intermediate time frame.42 Although
we randomized 146, rather than the prespecified 150, the preci-
sion of the estimates of treatment effect based on the 95% CIs
didnotincludeaclinicallysignificanteffect. Inthisstudyweused
an active comparator, benztropine, to reduce the potential of un-
blinding due to dry mouth. While benztropine has the potential
to improve LBP through its sedating effect, it is unlikely that this
occurred because a greater number of participants in the treat-
ment group reported an increased sleep duration at 6 months
than those in the benztropine group.
Conclusions
Theresultsofthistrialsuggestthattheuseoflow-doseamitripty-
line may be an effective treatment for chronic LBP. Although
we did not find statistically significant reductions in outcomes
at 6 months, the findings of a reduction in disability at 3 months,
an improvement in pain intensity that was nonsignificant at 6
months, and minimal adverse events with a low-dose, modest
sample size and active comparator, provide support for large-
scale clinical trials of low dose amitriptyline, with gradual dose
escalation. In the meantime, it may be worth trying low-dose
amitriptyline for these patients, especially if the only alterna-
tive is an opioid.
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